Multiple Sclerosis Drugs - Bulgaria

Bulgaria

The projected revenue in the Multiple Sclerosis Drugs market in Bulgaria is expected to reach US$10.00m in 2024.
It is anticipated that the revenue will demonstrate an annual growth rate (CAGR 2024-2029) of 1.08%, leading to a market volume of US$10.55m by 2029.
When compared globally, United States is expected to generate the highest revenue in the market, with an estimated value of US$11,770.00m in 2024.
Bulgaria's market for Multiple Sclerosis Drugs is experiencing a surge in demand due to increased awareness and improved access to healthcare services.

Key regions: France, India, United Kingdom, South Korea, Japan

Market

Region

Region comparison

Currency

Analyst Opinion

The Multiple Sclerosis Drugs market in Bulgaria has been showing steady growth in recent years.

Customer preferences: Patients suffering from Multiple Sclerosis in Bulgaria prefer oral medications over injectable ones. This preference is driven by the convenience of taking a pill as opposed to the discomfort and inconvenience of injections.

Trends in the market: The Multiple Sclerosis Drugs market in Bulgaria has been growing due to the increase in the number of diagnosed cases of Multiple Sclerosis in the country. This growth is also driven by the introduction of new drugs in the market that are more effective in treating the disease.

Local special circumstances: Bulgaria has a state-funded healthcare system, which means that the government regulates the prices of drugs. This has led to a decrease in the prices of Multiple Sclerosis drugs in the country, making them more affordable for patients.

Underlying macroeconomic factors: Bulgaria's economy has been growing steadily in recent years, which has led to an increase in healthcare spending. This has enabled the government to invest more in the healthcare system, including the treatment of Multiple Sclerosis. Additionally, the country's aging population has led to an increase in the number of diagnosed cases of Multiple Sclerosis, which has driven the growth of the market.In conclusion, the Multiple Sclerosis Drugs market in Bulgaria has been growing steadily due to the increase in the number of diagnosed cases of the disease, the introduction of new drugs, and the affordability of these drugs due to the state-funded healthcare system.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.